Your session is about to expire
← Back to Search
Stem Cell Transplant with T-allo10 Addback for Blood Diseases
Study Summary
This trial is studying a cell therapy called T-allo10 given after a stem cell transplant in order to help with the adaptive immune reconstitution while sparing the risk of developing severe Graft-versus-Host Disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am between 1 month and 45 years old and weigh at least 10 Kg.I have had a stem cell transplant and my bone marrow is making blood cells.I am over 18 and can consent, or if I can't, someone can on my behalf. If under 18, my guardian will consent and I'll agree if I'm over 7.I or my donor cannot undergo an extra cell collection procedure before donating cells for the study.I have a serious blood cancer and a stem cell transplant is recommended for me.You have taken part in another research study within the past month.I do not have severe graft-versus-host disease needing high-dose steroids.
- Group 1: Experimental: Stem Cell Transplant
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this trial cater to subjects aged 55 and over?
"Eligible participants for this trial must be aged between 1 Month and 45 years."
Who is eligible to participate in this clinical investigation?
"To qualify for this medical trial, applicants must be suffering from a hematologic disease and have an age ranging between one month to forty-five years old. At present, 22 individuals are being accepted into the study."
Does the Food and Drug Administration recognize T-allo10 cell supplementation as a viable treatment?
"Because the T-allo10 cells addback is currently in a trial's first phase, there is insufficient evidence demonstrating efficacy or safety. Therefore, Power assigned this pharmaceutical an initial score of 1."
What is the participant threshold for this medical trial?
"Affirmative. Clinicaltrials.gov confirms that this clinical trial, first posted on January 20th 2020 is actively recruiting participants. 22 patients are needed from 1 site in order to reach the desired sample size."
Are there any vacancies for this medical experiment currently available?
"Affirmative, the information available on clinicaltrials.gov indicates that this experiment is in search of participants. Initially posted to the website on January 20th 2020, it was last updated on March 25th 2022 and requires 22 people from a single medical site."
Share this study with friends
Copy Link
Messenger